CH676247A5 - - Google Patents

Download PDF

Info

Publication number: CH676247A5
Authority: CH; Switzerland
Prior art keywords: virus; recombinant; lav; htlv iii; sep
Prior art date: 1985-09-25

Application number

CH3821/86A

Other languages

English (en)

French (fr)

Inventor

Shiu-Lok Hu

Anthony F Purchio

Linda Madisen

Original Assignee

Oncogen

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1985-09-25

Filing date

1986-09-24

Publication date

1990-12-28

1986-09-24 Application filed by Oncogen filed Critical Oncogen

1990-12-28 Publication of CH676247A5 publication Critical patent/CH676247A5/fr

Links

241000598436 Human T-cell lymphotropic virus Species 0.000 claims abstract description 406
108090000623 proteins and genes Proteins 0.000 claims abstract description 402
241000700605 Viruses Species 0.000 claims abstract description 344
102000004169 proteins and genes Human genes 0.000 claims abstract description 252
238000000034 method Methods 0.000 claims abstract description 79
108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 71
230000014509 gene expression Effects 0.000 claims abstract description 36
239000000427 antigen Substances 0.000 claims abstract description 34
102000036639 antigens Human genes 0.000 claims abstract description 34
108091007433 antigens Proteins 0.000 claims abstract description 34
108020004511 Recombinant DNA Proteins 0.000 claims abstract description 33
230000000890 antigenic effect Effects 0.000 claims abstract description 25
229940031348 multivalent vaccine Drugs 0.000 claims abstract description 14
229940031626 subunit vaccine Drugs 0.000 claims abstract description 12
210000004027 cell Anatomy 0.000 claims description 230
241000700618 Vaccinia virus Species 0.000 claims description 139
229960005486 vaccine Drugs 0.000 claims description 85
208000015181 infectious disease Diseases 0.000 claims description 77
239000000203 mixture Substances 0.000 claims description 76
238000009472 formulation Methods 0.000 claims description 61
239000013598 vector Substances 0.000 claims description 57
206010046865 Vaccinia virus infection Diseases 0.000 claims description 46
208000007089 vaccinia Diseases 0.000 claims description 44
239000002773 nucleotide Substances 0.000 claims description 41
125000003729 nucleotide group Chemical group 0.000 claims description 41
241000701447 unidentified baculovirus Species 0.000 claims description 36
230000002458 infectious effect Effects 0.000 claims description 35
150000001413 amino acids Chemical class 0.000 claims description 30
108700004026 gag Genes Proteins 0.000 claims description 27
101150098622 gag gene Proteins 0.000 claims description 23
230000002163 immunogen Effects 0.000 claims description 23
238000004519 manufacturing process Methods 0.000 claims description 22
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 20
101710121417 Envelope glycoprotein Proteins 0.000 claims description 19
201000010099 disease Diseases 0.000 claims description 19
241000588724 Escherichia coli Species 0.000 claims description 13
241000894006 Bacteria Species 0.000 claims description 12
238000002360 preparation method Methods 0.000 claims description 12
244000005700 microbiome Species 0.000 claims description 11
230000008569 process Effects 0.000 claims description 11
241000238631 Hexapoda Species 0.000 claims description 10
241000701161 unidentified adenovirus Species 0.000 claims description 10
240000004808 Saccharomyces cerevisiae Species 0.000 claims description 7
125000000539 amino acid group Chemical group 0.000 claims description 7
210000004102 animal cell Anatomy 0.000 claims description 7
241000701366 unidentified nuclear polyhedrosis viruses Species 0.000 claims description 5
241001515965 unidentified phage Species 0.000 claims description 5
101710132601 Capsid protein Proteins 0.000 claims description 4
239000000546 pharmaceutical excipient Substances 0.000 claims 10
229940124531 pharmaceutical excipient Drugs 0.000 claims 10
125000003275 alpha amino acid group Chemical group 0.000 claims 5
102100021696 Syncytin-1 Human genes 0.000 claims 1
208000030507 AIDS Diseases 0.000 abstract description 55
102000004196 processed proteins & peptides Human genes 0.000 abstract description 41
206010001513 AIDS related complex Diseases 0.000 abstract description 16
238000003786 synthesis reaction Methods 0.000 abstract description 10
238000003018 immunoassay Methods 0.000 abstract description 8
239000003795 chemical substances by application Substances 0.000 abstract description 6
208000011580 syndromic disease Diseases 0.000 abstract description 4
208000031886 HIV Infections Diseases 0.000 abstract description 3
229960004854 viral vaccine Drugs 0.000 abstract 1
235000018102 proteins Nutrition 0.000 description 220
210000002966 serum Anatomy 0.000 description 100
108020004414 DNA Proteins 0.000 description 96
102000053602 DNA Human genes 0.000 description 96
239000013612 plasmid Substances 0.000 description 81
239000012634 fragment Substances 0.000 description 68
241001465754 Metazoa Species 0.000 description 44
238000010276 construction Methods 0.000 description 43
102100034349 Integrase Human genes 0.000 description 38
241000282553 Macaca Species 0.000 description 34
241000699670 Mus sp. Species 0.000 description 33
238000011081 inoculation Methods 0.000 description 33
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 31
238000004458 analytical method Methods 0.000 description 31
239000002609 medium Substances 0.000 description 29
102000006601 Thymidine Kinase Human genes 0.000 description 28
108020004440 Thymidine kinase Proteins 0.000 description 28
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 27
239000013604 expression vector Substances 0.000 description 27
239000002953 phosphate buffered saline Substances 0.000 description 27
239000000047 product Substances 0.000 description 25
230000003053 immunization Effects 0.000 description 24
238000002649 immunization Methods 0.000 description 24
238000003780 insertion Methods 0.000 description 24
230000037431 insertion Effects 0.000 description 24
210000005105 peripheral blood lymphocyte Anatomy 0.000 description 24
108091026890 Coding region Proteins 0.000 description 23
101710091045 Envelope protein Proteins 0.000 description 22
101000764559 Lactococcus phage c2 Probable tape measure protein Proteins 0.000 description 22
101710188315 Protein X Proteins 0.000 description 22
210000004698 lymphocyte Anatomy 0.000 description 21
101800001690 Transmembrane protein gp41 Proteins 0.000 description 20
238000002965 ELISA Methods 0.000 description 19
238000012360 testing method Methods 0.000 description 19
241000282414 Homo sapiens Species 0.000 description 18
239000000020 Nitrocellulose Substances 0.000 description 18
FJWGYAHXMCUOOM-QHOUIDNNSA-N [(2s,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6s)-4,5-dinitrooxy-2-(nitrooxymethyl)-6-[(2r,3r,4s,5r,6s)-4,5,6-trinitrooxy-2-(nitrooxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-3,5-dinitrooxy-6-(nitrooxymethyl)oxan-4-yl] nitrate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O)O[C@H]1[C@@H]([C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@@H](CO[N+]([O-])=O)O1)O[N+]([O-])=O)CO[N+](=O)[O-])[C@@H]1[C@@H](CO[N+]([O-])=O)O[C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O FJWGYAHXMCUOOM-QHOUIDNNSA-N 0.000 description 18
235000001014 amino acid Nutrition 0.000 description 18
229940024606 amino acid Drugs 0.000 description 18
230000028993 immune response Effects 0.000 description 18
229920001220 nitrocellulos Polymers 0.000 description 18
229940079938 nitrocellulose Drugs 0.000 description 18
230000000638 stimulation Effects 0.000 description 18
238000013519 translation Methods 0.000 description 18
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 17
108091028043 Nucleic acid sequence Proteins 0.000 description 17
238000010367 cloning Methods 0.000 description 17
239000000499 gel Substances 0.000 description 17
229960004452 methionine Drugs 0.000 description 17
230000006798 recombination Effects 0.000 description 17
230000004044 response Effects 0.000 description 17
239000006228 supernatant Substances 0.000 description 17
238000003556 assay Methods 0.000 description 16
238000001114 immunoprecipitation Methods 0.000 description 16
108091008146 restriction endonucleases Proteins 0.000 description 16
239000000523 sample Substances 0.000 description 16
239000000243 solution Substances 0.000 description 16
210000001519 tissue Anatomy 0.000 description 16
241000283707 Capra Species 0.000 description 15
108010002350 Interleukin-2 Proteins 0.000 description 15
102000000588 Interleukin-2 Human genes 0.000 description 15
101710182846 Polyhedrin Proteins 0.000 description 15
238000005119 centrifugation Methods 0.000 description 15
239000008188 pellet Substances 0.000 description 15
238000005215 recombination Methods 0.000 description 15
239000011780 sodium chloride Substances 0.000 description 15
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 15
229920001817 Agar Polymers 0.000 description 14
101150003725 TK gene Proteins 0.000 description 13
238000001962 electrophoresis Methods 0.000 description 13
238000001727 in vivo Methods 0.000 description 13
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
210000001744 T-lymphocyte Anatomy 0.000 description 12
239000002671 adjuvant Substances 0.000 description 12
239000013592 cell lysate Substances 0.000 description 12
108700004025 env Genes Proteins 0.000 description 12
238000002474 experimental method Methods 0.000 description 12
238000000338 in vitro Methods 0.000 description 12
210000004940 nucleus Anatomy 0.000 description 12
102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 11
108090000288 Glycoproteins Proteins 0.000 description 11
102000003886 Glycoproteins Human genes 0.000 description 11
101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 11
241000282579 Pan Species 0.000 description 11
238000013459 approach Methods 0.000 description 11
238000006243 chemical reaction Methods 0.000 description 11
101150030339 env gene Proteins 0.000 description 11
229920002401 polyacrylamide Polymers 0.000 description 11
238000011282 treatment Methods 0.000 description 11
101710094648 Coat protein Proteins 0.000 description 10
108060003951 Immunoglobulin Proteins 0.000 description 10
TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 10
238000001514 detection method Methods 0.000 description 10
238000009396 hybridization Methods 0.000 description 10
102000018358 immunoglobulin Human genes 0.000 description 10
238000011534 incubation Methods 0.000 description 10
-1 lysolecithin Chemical compound 0.000 description 10
238000003156 radioimmunoprecipitation Methods 0.000 description 10
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 10
238000013518 transcription Methods 0.000 description 10
230000035897 transcription Effects 0.000 description 10
210000002845 virion Anatomy 0.000 description 10
230000003612 virological effect Effects 0.000 description 10
102000002260 Alkaline Phosphatase Human genes 0.000 description 9
108020004774 Alkaline Phosphatase Proteins 0.000 description 9
108020004705 Codon Proteins 0.000 description 9
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 9
238000010790 dilution Methods 0.000 description 9
239000012895 dilution Substances 0.000 description 9
230000001900 immune effect Effects 0.000 description 9
230000036039 immunity Effects 0.000 description 9
238000002372 labelling Methods 0.000 description 9
229930182817 methionine Natural products 0.000 description 9
235000019333 sodium laurylsulphate Nutrition 0.000 description 9
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 8
101150098499 III gene Proteins 0.000 description 8
108700026244 Open Reading Frames Proteins 0.000 description 8
229920001213 Polysorbate 20 Polymers 0.000 description 8
102100029807 SUMO-conjugating enzyme UBC9 Human genes 0.000 description 8
239000008272 agar Substances 0.000 description 8
230000029087 digestion Effects 0.000 description 8
239000001963 growth medium Substances 0.000 description 8
239000007924 injection Substances 0.000 description 8
238000002347 injection Methods 0.000 description 8
239000006166 lysate Substances 0.000 description 8
108020004999 messenger RNA Proteins 0.000 description 8
239000002245 particle Substances 0.000 description 8
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 8
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 8
239000002243 precursor Substances 0.000 description 8
238000000746 purification Methods 0.000 description 8
229940083575 sodium dodecyl sulfate Drugs 0.000 description 8
241001430294 unidentified retrovirus Species 0.000 description 8
108091032973 (ribonucleotides)n+m Proteins 0.000 description 7
238000007900 DNA-DNA hybridization Methods 0.000 description 7
241000282577 Pan troglodytes Species 0.000 description 7
108010008038 Synthetic Vaccines Proteins 0.000 description 7
239000007983 Tris buffer Substances 0.000 description 7
239000013599 cloning vector Substances 0.000 description 7
230000015271 coagulation Effects 0.000 description 7
238000005345 coagulation Methods 0.000 description 7
230000012010 growth Effects 0.000 description 7
239000000543 intermediate Substances 0.000 description 7
238000002955 isolation Methods 0.000 description 7
101800002723 p18 Proteins 0.000 description 7
239000002504 physiological saline solution Substances 0.000 description 7
229940124551 recombinant vaccine Drugs 0.000 description 7
WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 6
102100024210 CD166 antigen Human genes 0.000 description 6
101710177291 Gag polyprotein Proteins 0.000 description 6
208000009889 Herpes Simplex Diseases 0.000 description 6
241000282412 Homo Species 0.000 description 6
101000980840 Homo sapiens CD166 antigen Proteins 0.000 description 6
101710125418 Major capsid protein Proteins 0.000 description 6
241000699666 Mus <mouse, genus> Species 0.000 description 6
241000288906 Primates Species 0.000 description 6
229930006000 Sucrose Natural products 0.000 description 6
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 6
102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 6
230000001580 bacterial effect Effects 0.000 description 6
230000015572 biosynthetic process Effects 0.000 description 6
210000004369 blood Anatomy 0.000 description 6
239000008280 blood Substances 0.000 description 6
239000000872 buffer Substances 0.000 description 6
238000012512 characterization method Methods 0.000 description 6
239000002299 complementary DNA Substances 0.000 description 6
230000006870 function Effects 0.000 description 6
230000005847 immunogenicity Effects 0.000 description 6
230000002779 inactivation Effects 0.000 description 6
239000003550 marker Substances 0.000 description 6
230000001404 mediated effect Effects 0.000 description 6
229920001184 polypeptide Polymers 0.000 description 6
230000037452 priming Effects 0.000 description 6
230000035755 proliferation Effects 0.000 description 6
238000003259 recombinant expression Methods 0.000 description 6
230000010076 replication Effects 0.000 description 6
239000005720 sucrose Substances 0.000 description 6
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 6
108091003079 Bovine Serum Albumin Proteins 0.000 description 5
241000282693 Cercopithecidae Species 0.000 description 5
102000004190 Enzymes Human genes 0.000 description 5
108090000790 Enzymes Proteins 0.000 description 5
108010001336 Horseradish Peroxidase Proteins 0.000 description 5
101100321817 Human parvovirus B19 (strain HV) 7.5K gene Proteins 0.000 description 5
208000008771 Lymphadenopathy Diseases 0.000 description 5
206010028980 Neoplasm Diseases 0.000 description 5
229930182555 Penicillin Natural products 0.000 description 5
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 5
230000001413 cellular effect Effects 0.000 description 5
230000000694 effects Effects 0.000 description 5
229940088598 enzyme Drugs 0.000 description 5
230000002068 genetic effect Effects 0.000 description 5
229960002442 glucosamine Drugs 0.000 description 5
230000036541 health Effects 0.000 description 5
238000007912 intraperitoneal administration Methods 0.000 description 5
229910001629 magnesium chloride Inorganic materials 0.000 description 5
235000013336 milk Nutrition 0.000 description 5
239000008267 milk Substances 0.000 description 5
210000004080 milk Anatomy 0.000 description 5
238000012986 modification Methods 0.000 description 5
229940126619 mouse monoclonal antibody Drugs 0.000 description 5
230000003472 neutralizing effect Effects 0.000 description 5
229940049954 penicillin Drugs 0.000 description 5
239000008363 phosphate buffer Substances 0.000 description 5
239000013600 plasmid vector Substances 0.000 description 5
239000000843 powder Substances 0.000 description 5
238000012545 processing Methods 0.000 description 5
241000894007 species Species 0.000 description 5
229960005322 streptomycin Drugs 0.000 description 5
239000000126 substance Substances 0.000 description 5
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
ISAVYTVYFVQUDY-UHFFFAOYSA-N 4-tert-Octylphenol Chemical compound CC(C)(C)CC(C)(C)C1=CC=C(O)C=C1 ISAVYTVYFVQUDY-UHFFFAOYSA-N 0.000 description 4
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
238000012286 ELISA Assay Methods 0.000 description 4
241000725303 Human immunodeficiency virus Species 0.000 description 4
239000012741 Laemmli sample buffer Substances 0.000 description 4
229920003171 Poly (ethylene oxide) Polymers 0.000 description 4
108091081024 Start codon Proteins 0.000 description 4
108700009124 Transcription Initiation Site Proteins 0.000 description 4
239000003242 anti bacterial agent Substances 0.000 description 4
210000003719 b-lymphocyte Anatomy 0.000 description 4
239000011230 binding agent Substances 0.000 description 4
238000009835 boiling Methods 0.000 description 4
AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 4
239000003153 chemical reaction reagent Substances 0.000 description 4
230000000295 complement effect Effects 0.000 description 4
238000007796 conventional method Methods 0.000 description 4
230000013595 glycosylation Effects 0.000 description 4
238000006206 glycosylation reaction Methods 0.000 description 4
239000002054 inoculum Substances 0.000 description 4
PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 4
230000000670 limiting effect Effects 0.000 description 4
208000018555 lymphatic system disease Diseases 0.000 description 4
230000004048 modification Effects 0.000 description 4
239000013641 positive control Substances 0.000 description 4
230000001681 protective effect Effects 0.000 description 4
102000005962 receptors Human genes 0.000 description 4
108020003175 receptors Proteins 0.000 description 4
238000011160 research Methods 0.000 description 4
208000024891 symptom Diseases 0.000 description 4
229940104230 thymidine Drugs 0.000 description 4
238000001890 transfection Methods 0.000 description 4
238000005406 washing Methods 0.000 description 4
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
102000010789 Interleukin-2 Receptors Human genes 0.000 description 3
108010038453 Interleukin-2 Receptors Proteins 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
241001467552 Mycobacterium bovis BCG Species 0.000 description 3
108010076504 Protein Sorting Signals Proteins 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
241000256251 Spodoptera frugiperda Species 0.000 description 3
241000191967 Staphylococcus aureus Species 0.000 description 3
101710172711 Structural protein Proteins 0.000 description 3
WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 3
229960000723 ampicillin Drugs 0.000 description 3
AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 3
229940088710 antibiotic agent Drugs 0.000 description 3
229960000190 bacillus calmette–guérin vaccine Drugs 0.000 description 3
239000001110 calcium chloride Substances 0.000 description 3
229910001628 calcium chloride Inorganic materials 0.000 description 3
244000309466 calf Species 0.000 description 3
238000004587 chromatography analysis Methods 0.000 description 3
ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 3
229960005542 ethidium bromide Drugs 0.000 description 3
238000001502 gel electrophoresis Methods 0.000 description 3
229940031551 inactivated vaccine Drugs 0.000 description 3
229910052500 inorganic mineral Inorganic materials 0.000 description 3
239000007788 liquid Substances 0.000 description 3
239000012139 lysis buffer Substances 0.000 description 3
210000004962 mammalian cell Anatomy 0.000 description 3
239000000463 material Substances 0.000 description 3
210000004379 membrane Anatomy 0.000 description 3
239000012528 membrane Substances 0.000 description 3
239000011707 mineral Substances 0.000 description 3
235000010755 mineral Nutrition 0.000 description 3
230000002093 peripheral effect Effects 0.000 description 3
238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 3
229920005862 polyol Polymers 0.000 description 3
150000003077 polyols Chemical class 0.000 description 3
230000002265 prevention Effects 0.000 description 3
101150045694 prt gene Proteins 0.000 description 3
238000010814 radioimmunoprecipitation assay Methods 0.000 description 3
229920006395 saturated elastomer Polymers 0.000 description 3
239000007787 solid Substances 0.000 description 3
239000012128 staining reagent Substances 0.000 description 3
238000012546 transfer Methods 0.000 description 3
ASWBNKHCZGQVJV-UHFFFAOYSA-N (3-hexadecanoyloxy-2-hydroxypropyl) 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)COP([O-])(=O)OCC[N+](C)(C)C ASWBNKHCZGQVJV-UHFFFAOYSA-N 0.000 description 2
102000040650 (ribonucleotides)n+m Human genes 0.000 description 2
MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 2
WONRDHPFOHAWOG-UHFFFAOYSA-N 2-chloronaphthalen-1-ol Chemical compound C1=CC=C2C(O)=C(Cl)C=CC2=C1 WONRDHPFOHAWOG-UHFFFAOYSA-N 0.000 description 2
241000714195 Aids-associated retrovirus Species 0.000 description 2
WOVKYSAHUYNSMH-UHFFFAOYSA-N BROMODEOXYURIDINE Natural products C1C(O)C(CO)OC1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-UHFFFAOYSA-N 0.000 description 2
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
108020004638 Circular DNA Proteins 0.000 description 2
241000186216 Corynebacterium Species 0.000 description 2
102000004163 DNA-directed RNA polymerases Human genes 0.000 description 2
108090000626 DNA-directed RNA polymerases Proteins 0.000 description 2
108010067770 Endopeptidase K Proteins 0.000 description 2
241001131785 Escherichia coli HB101 Species 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
239000006137 Luria-Bertani broth Substances 0.000 description 2
241000282567 Macaca fascicularis Species 0.000 description 2
206010029350 Neurotoxicity Diseases 0.000 description 2
108700020497 Nucleopolyhedrovirus polyhedrin Proteins 0.000 description 2
229910019142 PO4 Inorganic materials 0.000 description 2
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
239000004743 Polypropylene Substances 0.000 description 2
108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
239000012980 RPMI-1640 medium Substances 0.000 description 2
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
ABBQHOQBGMUPJH-UHFFFAOYSA-M Sodium salicylate Chemical compound [Na+].OC1=CC=CC=C1C([O-])=O ABBQHOQBGMUPJH-UHFFFAOYSA-M 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
230000024932 T cell mediated immunity Effects 0.000 description 2
208000000389 T-cell leukemia Diseases 0.000 description 2
208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 description 2
206010044221 Toxic encephalopathy Diseases 0.000 description 2
108020005202 Viral DNA Proteins 0.000 description 2
108010067390 Viral Proteins Proteins 0.000 description 2
238000010521 absorption reaction Methods 0.000 description 2
239000002253 acid Substances 0.000 description 2
238000004873 anchoring Methods 0.000 description 2
230000005875 antibody response Effects 0.000 description 2
230000002238 attenuated effect Effects 0.000 description 2
230000008901 benefit Effects 0.000 description 2
MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 2
230000003115 biocidal effect Effects 0.000 description 2
229940098773 bovine serum albumin Drugs 0.000 description 2
XJMXIWNOKIEIMX-UHFFFAOYSA-N bromo chloro 1h-indol-2-yl phosphate Chemical compound C1=CC=C2NC(OP(=O)(OBr)OCl)=CC2=C1 XJMXIWNOKIEIMX-UHFFFAOYSA-N 0.000 description 2
229950004398 broxuridine Drugs 0.000 description 2
239000001506 calcium phosphate Substances 0.000 description 2
229910000389 calcium phosphate Inorganic materials 0.000 description 2
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
230000008859 change Effects 0.000 description 2
238000003776 cleavage reaction Methods 0.000 description 2
230000009089 cytolysis Effects 0.000 description 2
229960003964 deoxycholic acid Drugs 0.000 description 2
KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
238000011161 development Methods 0.000 description 2
230000018109 developmental process Effects 0.000 description 2
230000004069 differentiation Effects 0.000 description 2
BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 2
239000000839 emulsion Substances 0.000 description 2
238000007824 enzymatic assay Methods 0.000 description 2
230000002255 enzymatic effect Effects 0.000 description 2
235000013861 fat-free Nutrition 0.000 description 2
239000012894 fetal calf serum Substances 0.000 description 2
238000012248 genetic selection Methods 0.000 description 2
238000010438 heat treatment Methods 0.000 description 2
XLYOFNOQVPJJNP-ZSJDYOACSA-N heavy water Substances [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 2
210000002443 helper t lymphocyte Anatomy 0.000 description 2
230000006801 homologous recombination Effects 0.000 description 2
238000002744 homologous recombination Methods 0.000 description 2
230000004727 humoral immunity Effects 0.000 description 2
230000008348 humoral response Effects 0.000 description 2
230000037111 immune power Effects 0.000 description 2
230000008105 immune reaction Effects 0.000 description 2
238000010166 immunofluorescence Methods 0.000 description 2
229940027941 immunoglobulin g Drugs 0.000 description 2
238000010324 immunological assay Methods 0.000 description 2
238000010348 incorporation Methods 0.000 description 2
230000001939 inductive effect Effects 0.000 description 2
230000000977 initiatory effect Effects 0.000 description 2
238000007918 intramuscular administration Methods 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
231100000518 lethal Toxicity 0.000 description 2
230000001665 lethal effect Effects 0.000 description 2
208000032839 leukemia Diseases 0.000 description 2
230000021633 leukocyte mediated immunity Effects 0.000 description 2
230000002101 lytic effect Effects 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
230000037230 mobility Effects 0.000 description 2
238000010369 molecular cloning Methods 0.000 description 2
230000007135 neurotoxicity Effects 0.000 description 2
231100000228 neurotoxicity Toxicity 0.000 description 2
FSVCQIDHPKZJSO-UHFFFAOYSA-L nitro blue tetrazolium dichloride Chemical compound [Cl-].[Cl-].COC1=CC(C=2C=C(OC)C(=CC=2)[N+]=2N(N=C(N=2)C=2C=CC=CC=2)C=2C=CC(=CC=2)[N+]([O-])=O)=CC=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=C([N+]([O-])=O)C=C1 FSVCQIDHPKZJSO-UHFFFAOYSA-L 0.000 description 2
229910052757 nitrogen Inorganic materials 0.000 description 2
239000003921 oil Substances 0.000 description 2
235000019198 oils Nutrition 0.000 description 2
230000003287 optical effect Effects 0.000 description 2
230000036961 partial effect Effects 0.000 description 2
235000021317 phosphate Nutrition 0.000 description 2
229920001983 poloxamer Polymers 0.000 description 2
229920000447 polyanionic polymer Polymers 0.000 description 2
229920001155 polypropylene Polymers 0.000 description 2
210000002729 polyribosome Anatomy 0.000 description 2
239000002244 precipitate Substances 0.000 description 2
230000002035 prolonged effect Effects 0.000 description 2
230000000644 propagated effect Effects 0.000 description 2
230000004224 protection Effects 0.000 description 2
238000003127 radioimmunoassay Methods 0.000 description 2
235000020185 raw untreated milk Nutrition 0.000 description 2
230000009257 reactivity Effects 0.000 description 2
230000002829 reductive effect Effects 0.000 description 2
230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 2
230000007017 scission Effects 0.000 description 2
238000007790 scraping Methods 0.000 description 2
206010040882 skin lesion Diseases 0.000 description 2
231100000444 skin lesion Toxicity 0.000 description 2
229940083538 smallpox vaccine Drugs 0.000 description 2
229960004025 sodium salicylate Drugs 0.000 description 2
238000007920 subcutaneous administration Methods 0.000 description 2
239000000758 substrate Substances 0.000 description 2
239000004094 surface-active agent Substances 0.000 description 2
238000009210 therapy by ultrasound Methods 0.000 description 2
230000009466 transformation Effects 0.000 description 2
230000001131 transforming effect Effects 0.000 description 2
230000014621 translational initiation Effects 0.000 description 2
238000011144 upstream manufacturing Methods 0.000 description 2
230000000007 visual effect Effects 0.000 description 2
DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 1
MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 1
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 1
LVSPDZAGCBEQAV-UHFFFAOYSA-N 4-chloronaphthalen-1-ol Chemical compound C1=CC=C2C(O)=CC=C(Cl)C2=C1 LVSPDZAGCBEQAV-UHFFFAOYSA-N 0.000 description 1
241000255974 Antheraea Species 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
208000031504 Asymptomatic Infections Diseases 0.000 description 1
102100022717 Atypical chemokine receptor 1 Human genes 0.000 description 1
241001203868 Autographa californica Species 0.000 description 1
241000201370 Autographa californica nucleopolyhedrovirus Species 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
241000711443 Bovine coronavirus Species 0.000 description 1
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
241000282552 Chlorocebus aethiops Species 0.000 description 1
108020004635 Complementary DNA Proteins 0.000 description 1
102000012410 DNA Ligases Human genes 0.000 description 1
108010061982 DNA Ligases Proteins 0.000 description 1
230000004543 DNA replication Effects 0.000 description 1
ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
102100038132 Endogenous retrovirus group K member 6 Pro protein Human genes 0.000 description 1
101000686824 Enterobacteria phage N4 Virion DNA-directed RNA polymerase Proteins 0.000 description 1
101000906736 Escherichia phage Mu DNA circularization protein N Proteins 0.000 description 1
101000644628 Escherichia phage Mu Tail fiber assembly protein U Proteins 0.000 description 1
PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
229920001917 Ficoll Polymers 0.000 description 1
108700039691 Genetic Promoter Regions Proteins 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 1
239000007995 HEPES buffer Substances 0.000 description 1
101000678879 Homo sapiens Atypical chemokine receptor 1 Proteins 0.000 description 1
101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 1
101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 description 1
101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
206010061598 Immunodeficiency Diseases 0.000 description 1
208000029462 Immunodeficiency disease Diseases 0.000 description 1
108020005350 Initiator Codon Proteins 0.000 description 1
102000014150 Interferons Human genes 0.000 description 1
108010050904 Interferons Proteins 0.000 description 1
208000007766 Kaposi sarcoma Diseases 0.000 description 1
XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
FFEARJCKVFRZRR-UHFFFAOYSA-N L-Methionine Natural products CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 description 1
ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
229930195722 L-methionine Natural products 0.000 description 1
COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
241000713102 La Crosse virus Species 0.000 description 1
102000004407 Lactalbumin Human genes 0.000 description 1
108090000942 Lactalbumin Proteins 0.000 description 1
108090001090 Lectins Proteins 0.000 description 1
102000004856 Lectins Human genes 0.000 description 1
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
102000008072 Lymphokines Human genes 0.000 description 1
108010074338 Lymphokines Proteins 0.000 description 1
206010025323 Lymphomas Diseases 0.000 description 1
206010025327 Lymphopenia Diseases 0.000 description 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
102100033468 Lysozyme C Human genes 0.000 description 1
PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
108010090054 Membrane Glycoproteins Proteins 0.000 description 1
102000012750 Membrane Glycoproteins Human genes 0.000 description 1
102000003792 Metallothionein Human genes 0.000 description 1
108090000157 Metallothionein Proteins 0.000 description 1
241000713333 Mouse mammary tumor virus Species 0.000 description 1
108010014251 Muramidase Proteins 0.000 description 1
108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
101710141454 Nucleoprotein Proteins 0.000 description 1
108091034117 Oligonucleotide Proteins 0.000 description 1
208000006440 Open Bite Diseases 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
108020002230 Pancreatic Ribonuclease Proteins 0.000 description 1
102000005891 Pancreatic ribonuclease Human genes 0.000 description 1
235000019483 Peanut oil Nutrition 0.000 description 1
241000364057 Peoria Species 0.000 description 1
108091005804 Peptidases Proteins 0.000 description 1
108010004729 Phycoerythrin Proteins 0.000 description 1
108010047620 Phytohemagglutinins Proteins 0.000 description 1
241000233870 Pneumocystis Species 0.000 description 1
RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
AWJGUZSYVIVZGP-YUMQZZPRSA-N Pro-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1 AWJGUZSYVIVZGP-YUMQZZPRSA-N 0.000 description 1
101710083689 Probable capsid protein Proteins 0.000 description 1
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
239000004365 Protease Substances 0.000 description 1
241000713126 Punta Toro virus Species 0.000 description 1
239000012083 RIPA buffer Substances 0.000 description 1
101000908388 Rattus norvegicus Dipeptidyl peptidase 4 Proteins 0.000 description 1
108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
102000004389 Ribonucleoproteins Human genes 0.000 description 1
108010081734 Ribonucleoproteins Proteins 0.000 description 1
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
241000700584 Simplexvirus Species 0.000 description 1
108020004682 Single-Stranded DNA Proteins 0.000 description 1
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
241000191940 Staphylococcus Species 0.000 description 1
101000764570 Streptomyces phage phiC31 Probable tape measure protein Proteins 0.000 description 1
102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 1
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
239000004473 Threonine Substances 0.000 description 1
239000013504 Triton X-100 Substances 0.000 description 1
229920004890 Triton X-100 Polymers 0.000 description 1
108090000631 Trypsin Proteins 0.000 description 1
102000004142 Trypsin Human genes 0.000 description 1
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
241000700646 Vaccinia virus WR Species 0.000 description 1
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
241000700647 Variola virus Species 0.000 description 1
241000710959 Venezuelan equine encephalitis virus Species 0.000 description 1
108010015780 Viral Core Proteins Proteins 0.000 description 1
108010003533 Viral Envelope Proteins Proteins 0.000 description 1
208000036142 Viral infection Diseases 0.000 description 1
102000018265 Virus Receptors Human genes 0.000 description 1
108010066342 Virus Receptors Proteins 0.000 description 1
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
LUXUAZKGQZPOBZ-SAXJAHGMSA-N [(3S,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] (Z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC1O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]1O LUXUAZKGQZPOBZ-SAXJAHGMSA-N 0.000 description 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
238000005299 abrasion Methods 0.000 description 1
230000021736 acetylation Effects 0.000 description 1
238000006640 acetylation reaction Methods 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
230000009471 action Effects 0.000 description 1
208000013228 adenopathy Diseases 0.000 description 1
239000011543 agarose gel Substances 0.000 description 1
235000004279 alanine Nutrition 0.000 description 1
230000004075 alteration Effects 0.000 description 1
229940037003 alum Drugs 0.000 description 1
ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 1
DIZPMCHEQGEION-UHFFFAOYSA-H aluminium sulfate (anhydrous) Chemical compound [Al+3].[Al+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O DIZPMCHEQGEION-UHFFFAOYSA-H 0.000 description 1
238000010171 animal model Methods 0.000 description 1
230000007503 antigenic stimulation Effects 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
235000009582 asparagine Nutrition 0.000 description 1
229960001230 asparagine Drugs 0.000 description 1
235000003704 aspartic acid Nutrition 0.000 description 1
238000013096 assay test Methods 0.000 description 1
WXNRAKRZUCLRBP-UHFFFAOYSA-N avridine Chemical compound CCCCCCCCCCCCCCCCCCN(CCCN(CCO)CCO)CCCCCCCCCCCCCCCCCC WXNRAKRZUCLRBP-UHFFFAOYSA-N 0.000 description 1
229950010555 avridine Drugs 0.000 description 1
MSWZFWKMSRAUBD-QZABAPFNSA-N beta-D-glucosamine Chemical compound N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-QZABAPFNSA-N 0.000 description 1
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
239000003124 biologic agent Substances 0.000 description 1
229960000074 biopharmaceutical Drugs 0.000 description 1
230000000740 bleeding effect Effects 0.000 description 1
210000000601 blood cell Anatomy 0.000 description 1
239000001045 blue dye Substances 0.000 description 1
210000001124 body fluid Anatomy 0.000 description 1
239000010839 body fluid Substances 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
210000000481 breast Anatomy 0.000 description 1
238000010804 cDNA synthesis Methods 0.000 description 1
WLZRMCYVCSSEQC-UHFFFAOYSA-N cadmium(2+) Chemical compound [Cd+2] WLZRMCYVCSSEQC-UHFFFAOYSA-N 0.000 description 1
235000011148 calcium chloride Nutrition 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
230000000711 cancerogenic effect Effects 0.000 description 1
210000000234 capsid Anatomy 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
231100000357 carcinogen Toxicity 0.000 description 1
239000003183 carcinogenic agent Substances 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
230000034303 cell budding Effects 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
208000011902 cervical lymphadenopathy Diseases 0.000 description 1
235000013351 cheese Nutrition 0.000 description 1
239000012829 chemotherapy agent Substances 0.000 description 1
VDQQXEISLMTGAB-UHFFFAOYSA-N chloramine T Chemical compound [Na+].CC1=CC=C(S(=O)(=O)[N-]Cl)C=C1 VDQQXEISLMTGAB-UHFFFAOYSA-N 0.000 description 1
210000000349 chromosome Anatomy 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
238000007820 coagulation assay Methods 0.000 description 1
238000004440 column chromatography Methods 0.000 description 1
238000012790 confirmation Methods 0.000 description 1
239000013078 crystal Substances 0.000 description 1
210000004748 cultured cell Anatomy 0.000 description 1
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
235000018417 cysteine Nutrition 0.000 description 1
230000000120 cytopathologic effect Effects 0.000 description 1
210000000805 cytoplasm Anatomy 0.000 description 1
210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
230000034994 death Effects 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
238000002405 diagnostic procedure Methods 0.000 description 1
229940061607 dibasic sodium phosphate Drugs 0.000 description 1
UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
229910000397 disodium phosphate Inorganic materials 0.000 description 1
235000019800 disodium phosphate Nutrition 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
239000003814 drug Substances 0.000 description 1
239000012636 effector Substances 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
238000009585 enzyme analysis Methods 0.000 description 1
238000000605 extraction Methods 0.000 description 1
239000011536 extraction buffer Substances 0.000 description 1
239000012091 fetal bovine serum Substances 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
238000001914 filtration Methods 0.000 description 1
239000012467 final product Substances 0.000 description 1
GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
108020001507 fusion proteins Proteins 0.000 description 1
102000037865 fusion proteins Human genes 0.000 description 1
238000005227 gel permeation chromatography Methods 0.000 description 1
238000010353 genetic engineering Methods 0.000 description 1
235000013922 glutamic acid Nutrition 0.000 description 1
239000004220 glutamic acid Substances 0.000 description 1
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
235000004554 glutamine Nutrition 0.000 description 1
150000004676 glycans Chemical class 0.000 description 1
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
229920001519 homopolymer Polymers 0.000 description 1
230000005745 host immune response Effects 0.000 description 1
210000005260 human cell Anatomy 0.000 description 1
210000005104 human peripheral blood lymphocyte Anatomy 0.000 description 1
229910052739 hydrogen Inorganic materials 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
239000005457 ice water Substances 0.000 description 1
238000007654 immersion Methods 0.000 description 1
230000014726 immortalization of host cell Effects 0.000 description 1
230000007813 immunodeficiency Effects 0.000 description 1
230000002998 immunogenetic effect Effects 0.000 description 1
239000012133 immunoprecipitate Substances 0.000 description 1
230000002480 immunoprotective effect Effects 0.000 description 1
230000036046 immunoreaction Effects 0.000 description 1
238000009169 immunotherapy Methods 0.000 description 1
239000000411 inducer Substances 0.000 description 1
239000012678 infectious agent Substances 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
230000003993 interaction Effects 0.000 description 1
229940079322 interferon Drugs 0.000 description 1
239000007928 intraperitoneal injection Substances 0.000 description 1
238000005342 ion exchange Methods 0.000 description 1
AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
229960000310 isoleucine Drugs 0.000 description 1
230000000366 juvenile effect Effects 0.000 description 1
210000003292 kidney cell Anatomy 0.000 description 1
239000002523 lectin Substances 0.000 description 1
201000002364 leukopenia Diseases 0.000 description 1
231100001022 leukopenia Toxicity 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
239000002502 liposome Substances 0.000 description 1
230000005923 long-lasting effect Effects 0.000 description 1
210000003141 lower extremity Anatomy 0.000 description 1
231100001023 lymphopenia Toxicity 0.000 description 1
230000002934 lysing effect Effects 0.000 description 1
239000004325 lysozyme Substances 0.000 description 1
229960000274 lysozyme Drugs 0.000 description 1
235000010335 lysozyme Nutrition 0.000 description 1
229910052748 manganese Inorganic materials 0.000 description 1
239000011572 manganese Substances 0.000 description 1
238000005259 measurement Methods 0.000 description 1
230000010534 mechanism of action Effects 0.000 description 1
MIKKOBKEXMRYFQ-WZTVWXICSA-N meglumine amidotrizoate Chemical compound C[NH2+]C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CC(=O)NC1=C(I)C(NC(C)=O)=C(I)C(C([O-])=O)=C1I MIKKOBKEXMRYFQ-WZTVWXICSA-N 0.000 description 1
125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 1
230000011987 methylation Effects 0.000 description 1
238000007069 methylation reaction Methods 0.000 description 1
239000002480 mineral oil Substances 0.000 description 1
235000010446 mineral oil Nutrition 0.000 description 1
230000000116 mitigating effect Effects 0.000 description 1
ZAHQPTJLOCWVPG-UHFFFAOYSA-N mitoxantrone dihydrochloride Chemical compound Cl.Cl.O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO ZAHQPTJLOCWVPG-UHFFFAOYSA-N 0.000 description 1
238000002156 mixing Methods 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
210000005087 mononuclear cell Anatomy 0.000 description 1
210000000865 mononuclear phagocyte system Anatomy 0.000 description 1
239000013642 negative control Substances 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
PGSADBUBUOPOJS-UHFFFAOYSA-N neutral red Chemical compound Cl.C1=C(C)C(N)=CC2=NC3=CC(N(C)C)=CC=C3N=C21 PGSADBUBUOPOJS-UHFFFAOYSA-N 0.000 description 1
238000007899 nucleic acid hybridization Methods 0.000 description 1
239000002777 nucleoside Substances 0.000 description 1
150000003833 nucleoside derivatives Chemical class 0.000 description 1
230000008520 organization Effects 0.000 description 1
238000012856 packing Methods 0.000 description 1
230000008506 pathogenesis Effects 0.000 description 1
230000001717 pathogenic effect Effects 0.000 description 1
239000000312 peanut oil Substances 0.000 description 1
210000005259 peripheral blood Anatomy 0.000 description 1
239000011886 peripheral blood Substances 0.000 description 1
210000003200 peritoneal cavity Anatomy 0.000 description 1
102000013415 peroxidase activity proteins Human genes 0.000 description 1
108040007629 peroxidase activity proteins Proteins 0.000 description 1
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
230000026731 phosphorylation Effects 0.000 description 1
238000006366 phosphorylation reaction Methods 0.000 description 1
230000001885 phytohemagglutinin Effects 0.000 description 1
201000000317 pneumocystosis Diseases 0.000 description 1
108700004029 pol Genes Proteins 0.000 description 1
101150088264 pol gene Proteins 0.000 description 1
230000008488 polyadenylation Effects 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
238000006116 polymerization reaction Methods 0.000 description 1
229920001282 polysaccharide Polymers 0.000 description 1
239000005017 polysaccharide Substances 0.000 description 1
230000015323 positive regulation of phagocytosis Effects 0.000 description 1
230000003449 preventive effect Effects 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
230000001566 pro-viral effect Effects 0.000 description 1
108010053725 prolylvaline Proteins 0.000 description 1
235000019419 proteases Nutrition 0.000 description 1
230000009145 protein modification Effects 0.000 description 1
230000005180 public health Effects 0.000 description 1
235000021251 pulses Nutrition 0.000 description 1
238000004445 quantitative analysis Methods 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
238000011084 recovery Methods 0.000 description 1
230000008929 regeneration Effects 0.000 description 1
238000011069 regeneration method Methods 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
230000003252 repetitive effect Effects 0.000 description 1
230000003362 replicative effect Effects 0.000 description 1
229920002477 rna polymer Polymers 0.000 description 1
238000005070 sampling Methods 0.000 description 1
229940016590 sarkosyl Drugs 0.000 description 1
108700004121 sarkosyl Proteins 0.000 description 1
238000003345 scintillation counting Methods 0.000 description 1
238000012216 screening Methods 0.000 description 1
239000006152 selective media Substances 0.000 description 1
235000004400 serine Nutrition 0.000 description 1
238000004088 simulation Methods 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000001632 sodium acetate Substances 0.000 description 1
235000017281 sodium acetate Nutrition 0.000 description 1
229910000029 sodium carbonate Inorganic materials 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
229960000999 sodium citrate dihydrate Drugs 0.000 description 1
KSAVQLQVUXSOCR-UHFFFAOYSA-M sodium lauroyl sarcosinate Chemical compound [Na+].CCCCCCCCCCCC(=O)N(C)CC([O-])=O KSAVQLQVUXSOCR-UHFFFAOYSA-M 0.000 description 1
238000001179 sorption measurement Methods 0.000 description 1
230000010473 stable expression Effects 0.000 description 1
238000010186 staining Methods 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
239000000725 suspension Substances 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
235000008521 threonine Nutrition 0.000 description 1
210000001541 thymus gland Anatomy 0.000 description 1
238000004448 titration Methods 0.000 description 1
238000012549 training Methods 0.000 description 1
230000002103 transcriptional effect Effects 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
230000010415 tropism Effects 0.000 description 1
239000012588 trypsin Substances 0.000 description 1
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
235000002374 tyrosine Nutrition 0.000 description 1
238000002604 ultrasonography Methods 0.000 description 1
239000012646 vaccine adjuvant Substances 0.000 description 1
229940124931 vaccine adjuvant Drugs 0.000 description 1
239000004474 valine Substances 0.000 description 1
230000009385 viral infection Effects 0.000 description 1
230000006490 viral transcription Effects 0.000 description 1
230000001018 virulence Effects 0.000 description 1
229910052725 zinc Inorganic materials 0.000 description 1
239000011701 zinc Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/14011—Baculoviridae
- C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
- C12N2710/14141—Use of virus, viral particle or viral elements as a vector
- C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

Life Sciences & Earth Sciences (AREA)
Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Genetics & Genomics (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Biophysics (AREA)
Bioinformatics & Cheminformatics (AREA)
Biochemistry (AREA)
Zoology (AREA)
Molecular Biology (AREA)
Wood Science & Technology (AREA)
General Health & Medical Sciences (AREA)
General Engineering & Computer Science (AREA)
Virology (AREA)
Biomedical Technology (AREA)
Biotechnology (AREA)
Physics & Mathematics (AREA)
Plant Pathology (AREA)
Gastroenterology & Hepatology (AREA)
Microbiology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Medicinal Chemistry (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

CH3821/86A 1985-09-25 1986-09-24 CH676247A5 (sv)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date
US77990985A	1985-09-25	1985-09-25
US84298486A	1986-03-27	1986-03-27
US90521786A	1986-09-09	1986-09-09

Publications (1)

Publication Number	Publication Date
CH676247A5 true CH676247A5 (sv)	1990-12-28

Family

ID=27419757

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CH3821/86A CH676247A5 (sv)	1985-09-25	1986-09-24

Country Status (22)

Country	Link
CN (1)	CN1020752C (sv)
AT (1)	ATA256786A (sv)
CH (1)	CH676247A5 (sv)
DE (1)	DE3690508T1 (sv)
DK (1)	DK455486A (sv)
ES (2)	ES2002490A6 (sv)
FI (1)	FI863848A7 (sv)
FR (1)	FR2587720A2 (sv)
GB (1)	GB2181435B (sv)
GR (1)	GR862412B (sv)
HU (1)	HU205780B (sv)
IE (1)	IE59314B1 (sv)
IL (1)	IL80073A (sv)
IT (1)	IT1195829B (sv)
MY (1)	MY103182A (sv)
NL (1)	NL8602422A (sv)
NO (1)	NO863803L (sv)
NZ (1)	NZ217645A (sv)
PT (1)	PT83434B (sv)
SE (4)	SE8604007L (sv)
WO (1)	WO1987002038A1 (sv)
YU (1)	YU46753B (sv)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1996024378A3 (en) *	1995-02-10	1996-11-14	Worcester Found Ex Biology	Delivery of exogenous compounds

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES8706824A1 (es) *	1985-04-08	1987-07-01	Genetic Systems Corp	Un metodo para preparar proteinas que son inmunologicamente reactivas con anticuerpos para virus asociados con linfadenopatia.
US4734362A (en) *	1986-02-03	1988-03-29	Cambridge Bioscience Corporation	Process for purifying recombinant proteins, and products thereof
US4925784A (en) *	1986-04-04	1990-05-15	Hoffmann-La Roche Inc.	Expression and purification of an HTLV-III gag/env gene protein
US4983387A (en) *	1986-05-19	1991-01-08	Viral Technologies Inc.	HIV related peptides, immunogenic antigens, and use therefor as subunit vaccine for AIDS virus
DE3750151T2 (de) *	1986-09-19	1994-12-01	Oncogen	Verwendung von aktivierten T-Lymphozyten zur Vorbereitung einer pharmazeutischen Zusammensetzung zur Behandlung von AIDS.
IE872748L (en) *	1986-10-16	1988-04-16	Arjomari Europ	Polypeptides derived from the evvelope gene of human¹immunodeficiency virus in recombinant baculovirus infected¹insect cells
JPS63258575A (ja) *	1986-12-15	1988-10-26	レプリゲン　コーポレーション	昆虫細胞中でつくられる組換えｈｉｖエンベロープタンパク
FR2610632B1 (fr) *	1987-02-11	1990-12-21	Pasteur Institut	Peptides caracteristiques des retrovirus d'immunodeficience humaine (virus hiv) leurs applications au diagnostic des infections dues a certains de ces virus et, le cas echeant, a la vaccination contre le sida
JP2948823B2 (ja) *	1987-01-16	1999-09-13	アンステイテユ・パストウール	ヒト免疫不全レトロウィルス（ｈｉｖ）関連抗原性ペプチド、そのウィルス感染の検出及びワクチンへの使用
US5681713A (en) *	1987-05-08	1997-10-28	Smithkline Beecham Corporation	Expression of heterologous proteins in Drosophila cells
GB8714802D0 (en) *	1987-06-24	1987-07-29	Proteus Biotech Ltd	Synthetic polypeptides
DE10399032I1 (de) *	1987-08-28	2004-01-29	Health Research Inc	Rekombinante Viren.
FR2620030B1 (fr) *	1987-09-07	1990-03-23	Transgene Sa	Vecteur d'expression des proteines du virus hiv-2, un agent causal du sida, culture cellulaire infectee ou transformee par ce vecteur, proteines obtenues, vaccin et anticorps obtenus
IL89118A0 (en) *	1988-02-03	1989-08-15	Microgenesys Inc	Vaccine containing polypeptides derived from the envelope gene of human immunodeficiency virus type 1
US5763160A (en) *	1988-02-12	1998-06-09	United Biomedical, Inc.	Synthetic peptides and process of using same for the detection of antibodies to human immunodeficiency virus (HIV) gp120 envelope protein, diagnosis of AIDS and pre-AIDS conditions and as vaccines
DE68917520T2 (de) *	1988-05-06	1995-01-05	Ferropas Ag	Verfahren und Systeme zur Herstellung von HIV-Antigenen.
US5043262A (en) *	1988-05-12	1991-08-27	Dana Farber Cancer Institute	Protein, sequences containing the VPU gene therefore, vectors, methods of preparation and use
AP129A (en) *	1988-06-03	1991-04-17	Smithkline Biologicals S A	Expression of retrovirus gag protein eukaryotic cells
US5614404A (en) *	1988-06-10	1997-03-25	Theriod Biologics, Incorporated	Self-assembled, defective, non-self-propagating lentivirus particles
WO1989012095A1 (en) *	1988-06-10	1989-12-14	Applied Biotechnology, Inc.	A method of evaluating recombinant vaccines against immunodeficiency virus
US5631154A (en) *	1988-06-10	1997-05-20	Therion Biologics, Incorporated	Self assembled, defective, non-self-propagating lentivirus particles
US5747324A (en) *	1988-06-10	1998-05-05	Therion Biologics Corporation	Self-assembled, defective, non-self-propagating lentivirus particles
US5665577A (en) *	1989-02-06	1997-09-09	Dana-Farber Cancer Institute	Vectors containing HIV packaging sequences, packaging defective HIV vectors, and uses thereof
DE69031735T2 (de) *	1989-04-18	1998-03-12	Applied Biotechnology Inc	Erzeugung von hybrid-genen und proteinen durch rekombination mittels viren
JP3034025B2 (ja) *	1989-06-01	2000-04-17	アプライド・バイオテクノロジー・インコーポレーテツド	自己アセンブルド欠損非自己増殖性ウイルス粒子
GB8923123D0 (en) *	1989-10-13	1989-11-29	Connaught Lab	A vaccine for human immunodeficiency virus
US5981276A (en) *	1990-06-20	1999-11-09	Dana-Farber Cancer Institute	Vectors containing HIV packaging sequences, packaging defective HIV vectors, and uses thereof
US5840312A (en) *	1991-05-02	1998-11-24	Institut Pasteur	Recombinant Bacillus anthracis strains unable to produce the lethal factor protein or edema factor protein
FR2676068B1 (fr) *	1991-05-02	1994-11-04	Pasteur Institut	Souches recombinantes immunogenes de b. anthracis - compositions immunogenes les contenant.
AU672372B2 (en) *	1991-11-08	1996-10-03	Pharmacia & Upjohn Company	Feline leukemia virus vaccines
EP0679088B1 (en)	1992-09-29	2002-07-10	Inhale Therapeutic Systems	Pulmonary delivery of active fragments of parathyroid hormone
DE4405810A1 (de)	1994-02-23	1995-08-24	Behringwerke Ag	Von einem Retrovirus aus der HIV-Gruppe abgeleitete Peptide und deren Verwendung
ATE416755T1 (de)	1994-03-07	2008-12-15	Nektar Therapeutics	Verfahren und zusammensetzung für die pulmonale darreichung von insulin
US6013506A (en) *	1995-06-05	2000-01-11	Wardley; Richard C.	Feline leukemia virus vaccines
DE59507617D1 (de) *	1995-09-06	2000-02-17	Schablonentechnik Kufstein Ag	Verfahren zum Herstellen einer Siebdruckschablone
US6723558B1 (en)	1996-01-23	2004-04-20	St. Jude Children's Research Hospital	Preparation and use of viral vectors for mixed envelope protein vaccines against human immunodeficiency viruses
US5741492A (en) *	1996-01-23	1998-04-21	St. Jude Children's Research Hospital	Preparation and use of viral vectors for mixed envelope protein vaccines against human immunodeficiency viruses
US20060165606A1 (en)	1997-09-29	2006-07-27	Nektar Therapeutics	Pulmonary delivery particles comprising water insoluble or crystalline active agents
US6309623B1 (en)	1997-09-29	2001-10-30	Inhale Therapeutic Systems, Inc.	Stabilized preparations for use in metered dose inhalers
US6565885B1 (en)	1997-09-29	2003-05-20	Inhale Therapeutic Systems, Inc.	Methods of spray drying pharmaceutical compositions
US7871598B1 (en)	2000-05-10	2011-01-18	Novartis Ag	Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
PT1458360E (pt)	2001-12-19	2011-07-13	Novartis Ag	Derivados de indole como agonistas do recetor s1p1

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0127839B1 (en) *	1983-05-27	1992-07-15	THE TEXAS A&M UNIVERSITY SYSTEM	Method for producing a recombinant baculovirus expression vector
US4662514A (en) *	1983-11-01	1987-05-05	Charleswater Products, Inc.	Electrically conductive polymeric tubes for static sensitive electronic devices
US9328391B1 (en) *	1984-08-22	2016-05-03	The United States Of America As Represented By The Secretary, Department Of Health And Human Services	Cloning and expression of HIV-1 DNA
IL76082A (en) *	1984-08-22	1991-07-18	Us Health	Molecular clones of the genome of htlv-iii and a process for the preparation thereof
GB8501473D0 (en) *	1985-01-21	1985-02-20	Pasteur Institut	Cloned dna sequences
EP0387915B1 (en) *	1984-10-18	1993-03-10	Institut Pasteur	F antigens of the human immunodeficiency virus, and their applications
CA1341423C (en) *	1984-10-31	2003-03-04	Paul A. Luciw	Recombinant proteins of viruses associated with lymphadenopathy syndrome and/or acquired immune deficiency syndrome
DE3588134T2 (de) *	1984-12-24	1997-03-20	Genentech Inc	Fusionen von AIDS-verwandten Polypeptiden
US4774175A (en) *	1985-03-01	1988-09-27	Centocor, Inc.	Immunochemical methods for the detection of antibody against HTLV-III
FI861626A7 (fi) *	1985-04-19	1986-10-20	Hoffmann La Roche	Foervaervat immunbristsyndrom (aids) -relaterat viralt rekombinant hoeljeprotein samt ett testfoerfarande foer aids.
FR2586427B1 (fr) *	1985-08-20	1988-12-09	Pasteur Institut	Sequences de nucleotides et de polypeptides issus du virus visna et leur application a des essais de diagnostic et a la production de compositions immunogenes

1986
- 1986-09-22 NZ NZ217645A patent/NZ217645A/xx unknown
- 1986-09-22 GR GR862412A patent/GR862412B/el unknown
- 1986-09-23 SE SE8604007A patent/SE8604007L/sv not_active Application Discontinuation
- 1986-09-23 IE IE252586A patent/IE59314B1/en not_active IP Right Cessation
- 1986-09-24 HU HU864072A patent/HU205780B/hu not_active IP Right Cessation
- 1986-09-24 GB GB8622987A patent/GB2181435B/en not_active Expired - Fee Related
- 1986-09-24 FI FI863848A patent/FI863848A7/sv not_active IP Right Cessation
- 1986-09-24 NO NO863803A patent/NO863803L/no unknown
- 1986-09-24 IT IT67730/86A patent/IT1195829B/it active
- 1986-09-24 DK DK455486A patent/DK455486A/da not_active Application Discontinuation
- 1986-09-24 CH CH3821/86A patent/CH676247A5/fr not_active IP Right Cessation
- 1986-09-24 ES ES8602123A patent/ES2002490A6/es not_active Expired
- 1986-09-25 AT AT0256786A patent/ATA256786A/de unknown
- 1986-09-25 FR FR8613414A patent/FR2587720A2/fr active Granted
- 1986-09-25 DE DE19863690508 patent/DE3690508T1/de not_active Withdrawn
- 1986-09-25 WO PCT/US1986/002002 patent/WO1987002038A1/en not_active Ceased
- 1986-09-25 YU YU165486A patent/YU46753B/sh unknown
- 1986-09-25 CN CN86106632A patent/CN1020752C/zh not_active Expired - Fee Related
- 1986-09-25 PT PT83434A patent/PT83434B/pt not_active IP Right Cessation
- 1986-09-25 NL NL8602422A patent/NL8602422A/nl not_active Application Discontinuation
- 1986-12-31 IL IL8007386A patent/IL80073A/en not_active IP Right Cessation
1987
- 1987-09-29 MY MYPI87002188A patent/MY103182A/en unknown
1988
- 1988-05-13 ES ES8801494A patent/ES2006941A6/es not_active Expired
1991
- 1991-10-14 SE SE9102974A patent/SE9102974L/sv not_active Application Discontinuation
- 1991-10-14 SE SE9102976A patent/SE9102976L/sv not_active Application Discontinuation
- 1991-10-14 SE SE9102975A patent/SE9102975L/sv not_active Application Discontinuation

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1996024378A3 (en) *	1995-02-10	1996-11-14	Worcester Found Ex Biology	Delivery of exogenous compounds
US6335436B1 (en)	1995-02-10	2002-01-01	Hybridon, Inc.	Oligonucleotides active against drug-resistant bacteria

Also Published As

Publication number	Publication date
SE8604007D0 (sv)	1986-09-23
NO863803D0 (no)	1986-09-24
IE59314B1 (en)	1994-02-09
NZ217645A (en)	1991-11-26
FI863848L (fi)	1987-03-26
ATA256786A (de)	1995-05-15
HU205780B (en)	1992-06-29
NO863803L (no)	1987-03-26
IT8667730A0 (it)	1986-09-24
GR862412B (en)	1987-01-23
SE9102974D0 (sv)	1991-10-14
IL80073A (en)	1995-01-24
SE8604007L (sv)	1987-03-26
HUT42133A (en)	1987-06-29
MY103182A (en)	1993-05-29
DK455486D0 (da)	1986-09-24
IE862525L (en)	1987-03-25
FI863848A7 (sv)	1987-03-26
DK455486A (da)	1987-03-26
SE9102974L (sv)	1993-04-15
ES2006941A6 (es)	1989-05-16
PT83434A (en)	1986-10-01
SE9102975D0 (sv)	1991-10-14
YU165486A (en)	1989-08-31
CN1020752C (zh)	1993-05-19
IL80073A0 (en)	1986-12-31
CN86106632A (zh)	1987-05-13
IT1195829B (it)	1988-10-27
GB2181435A (en)	1987-04-23
GB8622987D0 (en)	1986-10-29
FR2587720B2 (sv)	1995-02-10
ES2002490A6 (es)	1988-08-16
SE9102976L (sv)	1993-04-15
GB2181435B (en)	1990-01-10
FR2587720A2 (fr)	1987-03-27
WO1987002038A1 (en)	1987-04-09
YU46753B (sh)	1994-05-10
NL8602422A (nl)	1987-04-16
FI863848A0 (fi)	1986-09-24
PT83434B (pt)	1988-07-29
SE9102976D0 (sv)	1991-10-14
DE3690508T1 (sv)	1988-06-23
SE9102975L (sv)	1993-04-15

Legal Events

Date	Code	Title	Description
1997-05-15	PL	Patent ceased

Publication	Publication Date	Title
CH676247A5 (sv)	1990-12-28
JP4052667B2 (ja)	2008-02-27	組換えアライグマポックスウイルス、およびネコ免疫不全症ウイルス感染症に対する有効なワクチンとしてのその使用
AU636944B2 (en)	1993-05-13	Non-replicating recombinant-made retroviral particles used as antiviral agents and immunogens
PL188641B1 (pl)	2005-03-31	Szczepionka polienv przeciwko HIV, sposób wytwarzania szczepionki polienv,zastosowanie szczepionki polienv,zastosowanie przynajmniej jednego rekombinowanego białka env HIV lub przynajmniej jednego wektora DNA, który koduje ekspresję rekombinowanego białka env HIV, plazmid bifunkcjonalny.
Ahmad et al.	1994	Reduced virus load in rhesus macaques immunized with recombinant gp160 and challenged with simian immunodeficiency virus
US5747324A (en)	1998-05-05	Self-assembled, defective, non-self-propagating lentivirus particles
WO1991019803A1 (en)	1991-12-26	Self assembled, defective, nonself-propagating viral particles
Winter et al.	1995	Recombinant BCG strains expressing the SIVmac251nef gene induce proliferative and CTL responses against nef synthetic peptides in mice
JP2767078B2 (ja)	1998-06-18	Ｈｉｖ―１の分子クローンとその使用法
JPH01500161A (ja)	1989-01-26	Ａｉｄｓの原因ウィルスの糖蛋白質、該糖蛋白質の製造方法及びワクチン
ES2198400T3 (es)	2004-02-01	Vector que codifica particulas virales no autopropagantes, defectuosas, auto-ensambladas.
JPH11507515A (ja)	1999-07-06	遺伝的に改変したネコ免疫不全症ウイルス、およびネコ免疫不全症ウイルス感染症に対する有効なワクチンとしてのその使用
FI114318B (sv)	2004-09-30	Förfarande för framställning av rekombinantadenovirusvacciner
CN1981043B (zh)	2010-06-09	用于表达黄病毒科蛋白的重组慢病毒载体及其作为疫苗的应用
Van der Ryst et al.	1998	Study of the immunogenicity of different recombinant Mengo viruses expressing HIV1 and SIV epitopes
EP0276591B1 (fr)	1994-04-06	Vaccin constitué par un vecteur viral et ADN recombinant codant notamment pour la protéine p25 du virus agent causal du S.I.D.A.
Rencher et al.	1997	Eliciting HIV-1 envelope-specific antibodies with mixed vaccinia virus recombinants
PT95939A (pt)	1991-09-13	Processo de producao de particulas de hiv, tornadas recombinantes e nao replicativas, e de vacinas
JPS6368075A (ja)	1988-03-26	後天性免疫不全症候群に関するワクチンおよび免疫検定法
AU608205B2 (en)	1991-03-28	Vaccines against acquired immune deficiency syndrome
FR2593519A1 (fr)	1987-07-31	Vaccin contre le syndrome immunodeficitaire acquis et intermediaires pour la preparation de ce vaccin
CA2164297A1 (en)	1994-12-22	Mengovirus as a vector for expression of foreign polypeptides
Rutkowska	2002	The development of vaccine delivery systems based on presenting peptides on the surface of core protein VP7 of African horse sickness virus